Low dose of rituximab for children with chronic immune thrombocytopenia and a review of the literatures

Children's immune thrombocytopenic purpura (immune thrombocytopenic purpura, ITP) is a common childhood hemorrhagic disease, accounting for 25% to 30% of children with bleeding disorders. Clinical protracted illness, poor treatment of chronic / refractory ITP, so far still no specific method. Currently, the clinical application of rituximab (rituximab, rituximab) treatment of CD20 + lymphoma access to good effect, including for the treatment of ITP, including B lymphocytes associated with autoimmune disease or intractable autoimmune diseases such as safe and effective cell reduction .